FilingsTodayBoditech Med
At a glance
Boditech Med filed 37 disclosures in the last 12 months, including 6 buyback, 4 earnings, 4 insider and 1 5% holder. The most recent key filing was on Sep 22.
Revenue for 2025 was ₩162B, up 17.3% on 2024. Operating margin was 17.9% against 18.9% a year earlier. Debt was 15% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩93.3B and operating profit of ₩15B.
The 2025 annual report lists 601 employees with an average tenure of 5.5 years and average pay of ₩49.5M, #1470 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩153M each on average. It paid ₩150 per common share in cash dividends, against ₩150 a year earlier (+0%). 최의열 and related parties held 25.44% at year end.
From the 2025 annual report
Staff: 601 (267 men, 334 women), of whom 39 on fixed-term contracts. Total pay for the year: ₩30.3B. Directors and auditors: 5, paid ₩764.9M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩150 | ₩150 | ₩200 |
| Payout ratio | 13.8% | 12% | 16.9% |
| Yield (as filed) | 0.90% | 0.90% | 1.00% |
| Total cash dividends | ₩3.3B | ₩3.3B | ₩4.4B |
Largest shareholder
최의열 holds 21.31%; with 12 related parties the group holds 25.44% of common shares at year end (from 25.78% at the start of the year).
Auditor: 한영회계법인 · opinion: Unqualified.
Rankings: Low debt #79 of 1,372 · Operating margin #88 of 1,376
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.